scholarly journals Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers

2011 ◽  
Vol 6 (2) ◽  
pp. 320-329 ◽  
Author(s):  
Tingting Wang ◽  
Guoxiang Cai ◽  
Yunping Qiu ◽  
Na Fei ◽  
Menghui Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gut Microbiota ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Colorectal Cancer Patients

scholarly journals Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism

Oncotarget ◽  
2016 ◽  
Vol 7 (29) ◽  
pp. 46158-46172 ◽  
Author(s):  
Zhiliang Wei ◽  
Shougen Cao ◽  
Shanglong Liu ◽  
Zengwu Yao ◽  
Teng Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Pilot Study ◽  
Gut Microbiota ◽  
Cancer Patients ◽  
Prognostic Biomarker ◽  
Colorectal Cancer Patients

Su1994 ORAL IRON THERAPY PROMOTES A PROINFLAMMATORY GUT MICROBIOTA IN COLORECTAL CANCER PATIENTS WITH IRON DEFICIENCY ANAEMIA

2020 ◽  
Vol 158 (6) ◽  
pp. S-737-S-738
Author(s):  
Oliver Phipps ◽  
Mohammed Nabil Quraishi ◽  
Aditi Kumar ◽  
Edward Dickson ◽  
Oliver Ng ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Iron Deficiency ◽  
Gut Microbiota ◽  
Cancer Patients ◽  
Iron Deficiency Anaemia ◽  
Oral Iron ◽  
Iron Therapy ◽  
Deficiency Anaemia ◽  
Oral Iron Therapy ◽  
Colorectal Cancer Patients

scholarly journals 626 – Gut Microbiota from Colorectal Cancer Patients Enhances the Progression of Intestinal Adenoma in Apc Min/+Mice

2019 ◽  
Vol 156 (6) ◽  
pp. S-131-S-132
Author(s):  
Lu Li ◽  
Xiaofei Li ◽  
Yue Sun ◽  
Kui Jiang ◽  
Bangmao Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gut Microbiota ◽  
Cancer Patients ◽  
Colorectal Cancer Patients ◽  
Intestinal Adenoma

scholarly journals Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Shintaro Okumura ◽  
Yusuke Konishi ◽  
Megumi Narukawa ◽  
Yuki Sugiura ◽  
Shin Yoshimoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Stress Response ◽  
Gut Microbiota ◽  
Cohort Studies ◽  
Cancer Patients ◽  
Colorectal Cancer Patients ◽  
Inflammatory Phenotypes ◽  
Colorectal Tumours ◽  
Independent Cohort ◽  
Oncogenic Stress

AbstractEmerging evidence is revealing that alterations in gut microbiota are associated with colorectal cancer (CRC). However, very little is currently known about whether and how gut microbiota alterations are causally associated with CRC development. Here we show that 12 faecal bacterial taxa are enriched in CRC patients in two independent cohort studies. Among them, 2 Porphyromonas species are capable of inducing cellular senescence, an oncogenic stress response, through the secretion of the bacterial metabolite, butyrate. Notably, the invasion of these bacteria is observed in the CRC tissues, coinciding with the elevation of butyrate levels and signs of senescence-associated inflammatory phenotypes. Moreover, although the administration of these bacteria into ApcΔ14/+ mice accelerate the onset of colorectal tumours, this is not the case when bacterial butyrate-synthesis genes are disrupted. These results suggest a causal relationship between Porphyromonas species overgrowth and colorectal tumourigenesis which may be due to butyrate-induced senescence.

Plasma hPG80 circulating prograstin levels in cancer patients in Nigeria: Prolevcan study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3029-3029
Author(s):  
Omolara A. Fatiregun ◽  
Dominique Joubert ◽  
Berengere Vire ◽  
Abigail Anni Frances Simon-Hart ◽  
Olaniyi Andrew Adekeye ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Blood Test ◽  
Blood Levels ◽  
Breast Cancers ◽  
Potential Utility ◽  
Treatment Assessment ◽  
Colorectal Cancer Patients

3029 Background: Progastrin is a tumor-promoting peptide which is detectable in the blood of patients with different cancers. hPG80 (circulating progastrin) is produced by cancer cells. Recently it was reported that hPG80 is detected in the blood of cancer patients, suggesting its potential utility for cancer detection. In this Nigerian study, we assessed the performance of hPG80 in diagnosed cancer patients versus healthy volunteers. Methods: Plasma samples of 50 patients with breast (n = 41) and colorectal (n = 9) cancer, aged from 26 to 70 years, were assayed for hPG80 levels with the DxPG80 kit from ECS-Progastrin. The diagnostic performance (ROC AUC) of hPG80 was assessed compared to 50 healthy volunteers aged from 21 to 38 years. Results: Plasma hPG80 levels were significantly higher in cancer patients compared to controls (median values: 4.59 pM (IQR: 2.02-8.27 pM) vs 1.37 pM (IQR: 0-3.11 pM), p < 0.0001). The median value of hPG80level was 3.96 pM (IQR: 1.61-7.89 pM) for breast cancers and 6.43 pM (IQR: 2.80-15.86 pM) for colorectal cancer patients. ROC AUC for all cancers, breast cancer and colorectal cancer were 0.75, 0.74 and 0.82 respectively. There was no correlation between hPG80 blood levels with age or CA15.3 levels. Conclusions: Plasma hPG80 is a simple and relatively affordable blood test, it shows potential utility as a biomarker for cancer detection, monitoring and treatment assessment. Further prospective studies are needed to explore and confirm its potential.

Sign in / Sign up

Export Citation Format

Share Document